Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx – Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, Nov. 02, 2017 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tandem Diabetes Care, Inc. (NASDAQ:TNDM), CASI Pharmaceuticals, Inc. (NASDAQ:CASI), SAExploration Holdings, Inc. (NASDAQ:SAEX), Roka Bioscience, Inc. (NASDAQ:ROKA), VirnetX Holding Corp (NYSE:VHC), and PhaseRx, Inc. (NASDAQ:PZRX) including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

TNDM DOWNLOAD: http://Fundamental-Markets.com/register/?so=TNDM 

CASI DOWNLOAD: http://Fundamental-Markets.com/register/?so=CASI 

SAEX DOWNLOAD: http://Fundamental-Markets.com/register/?so=SAEX 

ROKA DOWNLOAD: http://Fundamental-Markets.com/register/?so=ROKA 

VHC DOWNLOAD: http://Fundamental-Markets.com/register/?so=VHC 

PZRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=PZRX 

 (You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Tandem Diabetes Care, Inc. (NASDAQ:TNDM), CASI Pharmaceuticals, Inc. (NASDAQ:CASI), SAExploration Holdings, Inc. (NASDAQ:SAEX), Roka Bioscience, Inc. (NASDAQ:ROKA), VirnetX Holding Corp (NYSE:VHC), and PhaseRx, Inc. (NASDAQ:PZRX) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. All information in this release was accessed November 1, 2017. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All amounts in millions (except per share amounts).

-----------------------------------------

TANDEM DIABETES CARE, INC. (TNDM) REPORT OVERVIEW

Tandem Diabetes Care's Recent Financial Performance

For the three months ended September 30, 2017 vs September 30, 2016, Tandem Diabetes Care reported revenue of $27.0 vs $12.3 (up 119.5%), diluted earnings per share -$3.09 vs -$9.73. For the twelve months ended December 31, 2016 vs December 31, 2015, Tandem Diabetes Care reported revenue of $84.2 vs $72.9 (up 15.5%), diluted earnings per share -$2.73 vs -$2.50.

To read the full Tandem Diabetes Care, Inc. (TNDM) report, download it here: http://Fundamental-Markets.com/register/?so=TNDM 

-----------------------------------------

CASI PHARMACEUTICALS, INC. (CASI) REPORT OVERVIEW

CASI Pharmaceuticals' Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, CASI Pharmaceuticals reported diluted earnings per share -$0.04 vs -$0.08. For the twelve months ended December 31, 2016 vs December 31, 2015, CASI Pharmaceuticals reported diluted earnings per share -$0.17 vs -$0.22. CASI Pharmaceuticals is expected to report earnings on 11/13/2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is -$0.04. The reported EPS for the same quarter last year was -$0.03.

To read the full CASI Pharmaceuticals, Inc. (CASI) report, download it here: http://Fundamental-Markets.com/register/?so=CASI 

-----------------------------------------

SAEXPLORATION HOLDINGS, INC. (SAEX) REPORT OVERVIEW

SAExploration's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, SAExploration reported revenue of $13.6 vs $57.0 (down 76.1%), diluted earnings per share -$1.91 vs $1.97. For the twelve months ended December 31, 2016 vs December 31, 2015, SAExploration reported revenue of $205.6 vs $228.1 (down 9.9%), diluted earnings per share -$6.13 vs -$84.55.

To read the full SAExploration Holdings, Inc. (SAEX) report, download it here: http://Fundamental-Markets.com/register/?so=SAEX 

-----------------------------------------

ROKA BIOSCIENCE, INC. (ROKA) REPORT OVERVIEW

Roka Bioscience's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Roka Bioscience reported revenue of $2.1 vs $1.8 (up 16.7%), diluted earnings per share -$3.56 vs -$4.31. For the twelve months ended December 31, 2016 vs December 31, 2015, Roka Bioscience reported revenue of $7.2 vs $6.0 (up 20.0%), diluted earnings per share -$17.42 vs -$21.18.

To read the full Roka Bioscience, Inc. (ROKA) report, download it here: http://Fundamental-Markets.com/register/?so=ROKA 

-----------------------------------------

VIRNETX HOLDING CORP (VHC) REPORT OVERVIEW

VirnetX's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, VirnetX reported revenue of $0.396 vs $0.398 (down 0.5%), diluted earnings per share -$0.07 vs -$0.10. For the twelve months ended December 31, 2016 vs December 31, 2015, VirnetX reported revenue of $1.550 vs $1.555 (down 0.3%), diluted earnings per share -$0.51 vs -$0.56. VirnetX is expected to report earnings on 11/08/2017. According to Zacks Investment Research, based on 1 analysts forecasts, the consensus EPS forecast for the quarter is -$0.19. The reported EPS for the same quarter last year was -$0.13.

To read the full VirnetX Holding Corp (VHC) report, download it here: http://Fundamental-Markets.com/register/?so=VHC 

-----------------------------------------

PHASERX, INC. (PZRX) REPORT OVERVIEW

PhaseRx's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, PhaseRx reported diluted earnings per share -$0.30 vs -$1.84. For the twelve months ended December 31, 2016 vs December 31, 2015, PhaseRx reported diluted earnings per share -$2.68 vs -$14.22.

To read the full PhaseRx, Inc. (PZRX) report, download it here: http://Fundamental-Markets.com/register/?so=PZRX 

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade—and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2017 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.